DLL3 and neuroendocrine carcinoma: Future clinical trials should also focus on evaluating DLL3-targeted therapies in GEP-NEC, pulmonary LCNEC as well as pulmonary carcinoids, and should also investigate the potential role of DLL3 expression as a biomarker to refine patient selection.